Last month, Tandem Diabetes Care (NSDQ:TNDM) announced that the FDA approved its t:slim X2 insulin pump integrated with Dexcom‘s (NSDQ:DXCM) G5 mobile continuous glucose monitor.
The San Diego, Calif.-based company made the software available to its current t:slim X2 pump users at no additional cost, enabling them to add CGM-integration to their existing devices.
Today, the company reported that one-third of t:slim X2 pump users have updated their pumps to integrate Dexcom’s glucose monitoring tech. Of those who have taken Tandem up on the software update, more than 85% said they were satisfied or extremely satisfied with the process, the company said.
“We are demonstrating our continued commitment to customer care by providing a simple, efficient and cost-effective way for people to keep up with our latest technology,” president & CEO Kim Blickenstaff said in prepared remarks.
“We are the first and only company to offer its customers the ability to remotely update their insulin pump software using their personal computer. The rapid uptake and high satisfaction scores we’ve received since launch further validate our strategy and vision that modern technology can improve the lives of people with diabetes.”
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
